Candriam S.C.A. Has $38.57 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Candriam S.C.A. cut its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,154 shares of the biotechnology company's stock after selling 2,177 shares during the period. Candriam S.C.A. owned 0.46% of Ascendis Pharma A/S worth $38,569,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ASND. Jackson Square Capital LLC acquired a new stake in Ascendis Pharma A/S in the third quarter valued at $1,441,000. Assetmark Inc. acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $331,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $1,212,000. Oppenheimer Asset Management Inc. raised its holdings in shares of Ascendis Pharma A/S by 10.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 7,622 shares of the biotechnology company's stock worth $1,138,000 after purchasing an additional 695 shares during the period. Finally, Sivik Global Healthcare LLC acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $1,493,000.

Ascendis Pharma A/S Trading Down 3.8 %

ASND stock traded down $5.77 on Friday, hitting $145.74. 350,979 shares of the company's stock traded hands, compared to its average volume of 452,027. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $158.00. The stock has a market cap of $8.84 billion, a price-to-earnings ratio of -20.53 and a beta of 0.64. The stock has a fifty day moving average of $137.16 and a 200-day moving average of $134.36.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ASND has been the topic of a number of research reports. TD Cowen dropped their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, February 18th. Wedbush reissued an "outperform" rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, Oppenheimer lowered their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus target price of $202.36.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.